SURF - Surface Oncology, Inc.
| Previous Close | 2.2400 |
| Open | 2.3100 |
| Bid | 2.2600 x 800 |
| Ask | 2.2800 x 1000 |
| Day's Range | 2.2404 - 2.4379 |
| 52 Week Range | 1.1500 - 9.0800 |
| Volume | 47,217 |
| Avg. Volume | 89,209 |
| Market Cap | 63.294M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Surface Oncology, Inc. (SURF) Reports Q3 Loss, Lags Revenue Estimates
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -5.17% and -86.24%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Here's Why Surface Oncology (NASDAQ:SURF) Must Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- Zacks
Surface Oncology, Inc. (SURF) Reports Q2 Loss, Lags Revenue Estimates
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -3.23% and -94.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Will Surface Oncology, Inc. (SURF) Report Negative Q2 Earnings? What You Should Know
Surface Oncology, Inc. (SURF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Investors Who Bought Surface Oncology (NASDAQ:SURF) Shares A Year Ago Are Now Down 79%
It's not a secret that every investor will make bad investments, from time to time. But it's not unreasonable to try...
GuruFocus.comAnalysts Recommend These 3 Falling Knives
The following companies can be considered "falling knives" because their share prices have declined more than 59% over the past 52 weeks through May 30. Wall Street is also optimistic about them as it issued recommendation ratings ranging from overweight to buy with average target prices that produce at least 135% stock appreciation within 52 weeks. Warning! GuruFocus has detected 3 Warning Signs with PTE.
- Zacks
Surface Oncology, Inc. (SURF) Reports Q1 Loss, Tops Revenue Estimates
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of 65.91% and 477.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Could Surface Oncology, Inc.’s (NASDAQ:SURF) Investor Composition Influence The Stock Price?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Every investor in Surface Oncology, Inc. (NASDAQ:SURF) should be awareRead More...
